Domantis Limited

Bristol-myers Squibb Compnay

Biosceptre (aust) Pty Ltd

Abbott Laboratories Corporation

Istituto Superiore Di Sanita

Biosceptre International Limited

Steven Grant

Aaron Paul Yamniuk

Suzanne J Suchard

James William Bryson

James K Tamura

Philip Drew

Anish Suri

Steven G Nadler

Olga Ignatovich

Robert P Rehfuss

Laura Price

Julian Alexander Barden

Philip Jones

Haiqun Liu

Neil Brewis

Kevin Moulder

Steven Sheriff

Stanley Krystek

Chung-Ming Hsieh

Ian M Tomlinson

Michael Roguska

Yuliya Kutskova

John Memmott

Mihriban Tuna

Antonio Cassone

Bradford L McRae

Flavia De Bernardis

Carrie Enever

James Tamura

The invention relates to an antigen binding site for binding to a P2Xreceptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

Anti P2X7 receptor antibodies and fragments thereof

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA) or another antigen.

Antibody polypeptides that antagonize CD40L

Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single Vor Vdomain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).

Methods of treating immune diseases by administering antibody polypeptides that antagonize CD40

Anti P2Xreceptor antibodies and fragments thereof

Nucleic acids encoding antibody polypeptides that antagonize CD40

Methods of treating immune diseases by administering antibody polypeptides that specifically bind CD40L

The invention relates to an antigen binding site for binding to a P2Xreceptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

[object Object]

Antibody polypeptides that antagonize CD40

The invention relates to an antigen binding site for binding to a P2Xreceptor, the antigen binding site being defined by general formula 1:FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

Nucleic acids encoding antibody polypeptides that antagonize CD40L

The invention relates to antibody polypeptides that monovalently bind CD40L. Antibody polypeptides that are monovalent for binding of CD40L can inhibit CD40L activity while avoiding potential undesirable effects that can occur with antibodies capable of divalent or multivalent binding of CD40L. In one aspect, a monovalent anti-CD40L antibody polypeptide consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD40L, preferably without substantially agonizing CD40 and/or CD40L activity. In another aspect, the monovalent anti-CD40L antibody polypeptide is a human antibody polypeptide. The invention further encompasses methods of antagonizing CD40/CD40L interactions in an individual and methods of treating diseases or disorders involving CD40/CD40L interactions, the methods involving administering a monovalent anti-CD40L antibody polypeptide to the individual.

Methods of antagonizing the binding of CD40 to CD40L with CD40L-specific monovalent polypeptides in autoimmune individuals

Growing community of inventors

Cambridge, United Kingdom

Steven Grant